Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

Cellectis CRISPR patent CAR T research

News and Trends 16 Feb 2018

French Biotech Gets a CRISPR Patent for CAR-T Research

Update (16/02/2018): On top of the European patent it got last July, Cellectis now also has two US patents to use CRISPR technology to make CAR-T cells. Cellectis has said it will offer licenses to companies that want to use CRISPR gene editing in T cells. Not just for inserting CAR antigens, but also other editions […]

February 16, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Cellnovo insulin pump diabetes management

News and Trends 15 Feb 2018

This Mobile Diabetes Management System Can Reduce Hypoglycemia by 39%

The wireless system for diabetes management developed by Cellnovo can significantly reduce life-threatening events of hypoglycemia in patients with type 1 diabetes. A clinical study that followed type 1 diabetes patients for a year has concluded that a new mobile system for diabetes management could reduce events of hypoglycemia by 29% in adults — from […]

February 15, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

ibionext growth fund bpifrance

News and Trends 15 Feb 2018

Startup Studio Raises €90M to Create and Develop Exciting Young Biotechs

iBionext has closed its Growth Fund, which has raised money from investors like Bpifrance to help young biotechs to reach their potential. iBionext is a French ‘startup studio’ that specializes in the creation and development of startups in the healthcare industry. It has closed its iBionext Growth Fund at €90M, which will be used to finance […]

February 15, 2018 - 3 minutesmins - By Alex Dale

Peter Llewellyn Davies thumbnail 1

Interview 14 Feb 2018

This Biotech Veteran Is Using These Tips for Successful Drug Development, Here Is Why

Our second interview at Refresh in Vienna was with Peter Llewellyn-Davies, the founder of Accellerate Partners and Apeiron’s CFO and CBO. He told us how he found himself at the biotech and shared the lessons he learned on his way there. Peter Llewellyn-Davies founded Accellerate Partners in 2012, which offers services including corporate expansion, funding […]

February 14, 2018 - 5 minutesmins - By Alex Dale

antibiotic resistance phase III allecra 1

News and Trends 14 Feb 2018

Anti-Antibiotic Resistance Technology Gets Fast-Tracked to Phase III

Allecra Therapeutics’ candidate that blocks the development of antibiotic resistance has been awarded the FDA’s Fast Track Designation and will enter Phase III this summer. Allecra Therapeutics, our biotech of the week a few weeks ago, develops new treatments for multidrug-resistant Gram-negative bacterial infections. The company has received Fast Track Designation from the FDA and will begin […]

February 14, 2018 - 2 minutesmins - By Alex Dale

bicycle therapeutics solid tumors trial 1

News and Trends 14 Feb 2018

Bicycle’s First Peptide-Toxin Conjugate Enters the Clinic for Solid Tumors

A collaboration between Bicycle Therapeutics and Cancer Research UK has yielded its first peptide to enter clinical trials for solid tumors. Bicycle Therapeutics, the pioneer of the bicyclic peptide platform, has dosed the first patient in a Phase I/IIa trial with its solid tumors candidate, BT1718. The study will test the drug’s safety and efficacy in […]

February 14, 2018 - 3 minutesmins - By Alex Dale

ADVERTISEMENT

artificial intelligence peptides nuritas 1

News and Trends 14 Feb 2018

Nestlé and AI Biotech Hunt Down Bioactive Peptides in Our Food

Nuritas and Nestlé will use artificial intelligence to find bioactive peptides in the food we eat for applications including diabetes, anti-aging, and animal and plant health. Nuritas wants to revolutionize the discovery of natural active ingredients that can support and improve human health. The company uses artificial intelligence (AI) to look closely at the foods we […]

February 14, 2018 - 3 minutesmins - By Alex Dale

blindness deafness usher syndrome proqr2 1

News and Trends 13 Feb 2018

ProQR Tackles Blindness Caused by a Rare Genetic Disease

ProQR has received €6M from the American charity, Foundation Fighting Blindness, for the development of its treatment for Usher Syndrome – the leading cause of combined blindness and deafness. ProQR focuses on the development of RNA-based medicines for genetic diseases like cystic fibrosis. However, it is the company’s program targeting Usher syndrome, the leading cause of combined […]

February 13, 2018 - 3 minutesmins - By Alex Dale

ozempic novo nordisk diabetes

News and Trends 13 Feb 2018

Watch Out Eli Lilly: Novo’s Diabetes Drug Ozempic Gets European Approval

Update (13/02/2018): The European Commission has given Novo Nordisk a market authorization for Ozempic (semaglutide), bringing the competition for Eli Lilly’s Trulicity over to Europe. Eli Lilly executives have said that they are not worried by Novo’s competition, and keep confident on the performance of Trulicity, which now tops 40% of the market share of diabetes drugs belonging […]

February 13, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

breast cancer treatment erytech 1

News and Trends 13 Feb 2018

Erytech’s ‘Armed’ Red Blood Cells Will be Tested Against Triple Negative Breast Cancer

Erytech will test its Graspa technology for the treatment of a second solid tumor indication, breast cancer, following its success in pancreatic cancer. French biotech Erytech has developed an exciting platform for the treatment of cancer called Graspa, which encapsulates L-asparaginase in red blood cells. The company is now organizing a Phase II study for its next disease […]

February 13, 2018 - 2 minutesmins - By Alex Dale

fast wound healing prevents infection2 1

News and Trends 13 Feb 2018

High-Speed Healing Could Prevent the Infection of Chronic Wounds

Swedish scientists have used bacteria to deliver a chemical into wounds that speeds up the healing process. This could help to prevent their infection with dangerous strains of resistant bacteria. Researchers at Uppsala University have identified a technique to accelerate the wound healing process and reduce the chance of infection. The study, published in PNAS, […]

February 13, 2018 - 3 minutesmins - By Alex Dale

alzheimers treatment fail boehringer2 1

News and Trends 12 Feb 2018

No Nonsense Boehringer Ingelheim Jettisons Failing Alzheimer’s Disease Drug

Boehringer Ingelheim has ditched its Alzheimer’s drug after it failed to meet the endpoints of a Phase II trial but will continue to look at it for the treatment of schizophrenia. One of Germany’s biggest pharma companies, Boehringer Ingelheim, has given up on the development of its Alzheimer’s drug, BI 409306, which underwent Phase II testing. The […]

February 12, 2018 - 3 minutesmins - By Alex Dale

ADVERTISEMENT